Becton Dickinson and Company (BDX) closed its trading session on September 18, 2026, at USD 180.94 on the New York Stock Exchange. The stock experienced a modest decline of 0.24%, dropping by approximately USD 0.44 from the previous close of USD 181.38. Despite this slight downturn, the shares remained within their established intraday trading range, indicating a contained adjustment rather than a significant break in market structure or capitalization trends. Market attention for BDX is currently focused on recent regulatory developments involving an SEC cease and desist settlement regarding past risk disclosures related to Alaris infusion pumps. This legal resolution includes the imposition of a civil penalty and the establishment of a Fair Fund intended to compensate affected investors. Market participants are actively assessing the potential implications of these terms on the company's reputation, future compliance costs, and its standing within the broader healthcare regulatory environment. In addition to regulatory news, Becton Dickinson has a quarterly dividend scheduled for payment on September 30, 2026. This upcoming cash return is expected to influence sentiment among income-focused investors as the ex-dividend date approaches. The company's market capitalization was reported at approximately USD 52 billion during the session, reflecting its status as a major player in the medical device sector. The stock's performance on September 18 contrasted with mixed broader market conditions, where the Dow Jones Industrial Average slipped while the Nasdaq Composite posted gains. BDX's decline slightly lagged the technology-heavy Nasdaq but aligned more closely with the softer performance of the Dow, suggesting that company-specific factors and regulatory headlines played a larger role in shaping its price action than general index direction.